Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,044 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851

Conditions
CLL, Chronic Disease, Disease Attributes, +18 more
Locations
  • Highlands Oncology Group ( Site 5405) Springdale, Arkansas, United States
  • MemorialCare Health System - Long Beach Medical Center ( Site 5421) Long Beach, California, United States
  • Memorial Hospital West ( Site 5410) Pembroke Pines, Florida, United States
  • Oregon Health and Science University ( Site 5425) Portland, Oregon, United States
View all 67 locations
View Trial Details
Recruiting

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +19 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details
Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • USA Mitchell Cancer Institute ( Site 0014) Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0059) Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) Phoenix, Arizona, United States
  • Arizona Oncology Associates - NAHOA ( Site 8007) Prescott, Arizona, United States
View all 203 locations
View Trial Details
Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Mayo Clinic - Arizona Scottsdale, Arizona, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
View all 185 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Southern California /ID# 272414 Los Angeles, California, United States
  • Dana-Farber Cancer Institute /ID# 271846 Boston, Massachusetts, United States
  • University of Michigan Health System - Ann Arbor /ID# 271536 Ann Arbor, Michigan, United States
  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214 New York, United States
View all 50 locations
View Trial Details

Related conditions